Interestingly, the differential effects on downstream mTOR targets, such as increased active p70 in GDM-I but decreased active p70 in GDM-D placentas, suggest distinct metabolic adjustments depending on treatment type. The gene discussed is MTOR; the disease is gestational diabetes.